Convalescent plasma to treat COVID-19
Evan M. Bloch
Abstract
In this issue of Blood, Hegerova et al report on a study of 20 hospitalized patients with severe or critical coronavirus disease 2019 (COVID-19) who were transfused with convalescent plasma (CP); the authors suggest a favorable, albeit modest, benefit as compared with 20 matched (ie, nontransfused) controls, particularly when transfusion was undertaken within the first 7 days of hospitalization.(1)
Topics & Concepts
Convalescent plasmaCoronavirus disease 2019 (COVID-19)VirologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakMedicinePneumoniaImmunologyInternal medicineOutbreakInfectious disease (medical specialty)DiseaseCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19COVID-19 Impact on Reproduction